Personalized mRNA Melanoma Vaccine Extends Recurrence-Free Survival in Phase 3
TL;DR Summary
Moderna and Merck reported Phase 3 results for intismeran autogene (a personalized mRNA cancer vaccine) combined with Keytruda in high-risk melanoma patients after surgery, showing longer recurrence-free and metastasis-free survival versus Keytruda alone; safety was consistent with prior data. If confirmed, the vaccine could reshape cancer prevention and treatment and bolster mRNA vaccine credibility, but overall survival results and external validation are still pending.
- Moderna and Merck’s mRNA Melanoma Vaccine Looks Like a Game Changer Gizmodo
- How Moderna Nearly Tripled Its Stock Price in a Single Day The New York Times
- Moderna just made a huge leap forward in the world of cancer vaccines. Here’s what to know. The Boston Globe
- Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar CNBC
- Moderna’s 177% Surge Burns Shorts in ‘Painful’ $5.5 Billion Loss Bloomberg.com
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
4 min
vs 4 min read
Condensed
92%
779 → 64 words
Want the full story? Read the original article
Read on Gizmodo